Figure 1. Sequential use of tyrosine kinase inhibitors can select for cells harboring compound kinase domain mutations.

Schematic of sequential kinase inhibitor therapy and predicted BCR-ABL kinase domain (KD) genotypes of dasatinib-resistant cases treated after imatinib failure. Blue box represents imatinib-resistant, dasatinib-sensitive mutation.